New drug combo for advanced prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new drug (QLH12016) combined with a standard hormone therapy for men with advanced prostate cancer that has spread. The goal is to see if the combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 18 or older.
- You have prostate cancer that has spread to other parts of the body.
- You have had some previous cancer treatments, but not the specific type of drug being studied (AR PROTAC).
- You have not had other cancer treatments or major surgery in the past few weeks.
- You are generally well enough to be up and about, with a life expectancy of at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two study drugs for people with advanced prostate cancer that has spread or is no longer responding to hormone therapy. The goal is to see if the combination is safe and works against the cancer.
This trial tests two new drugs (QLC5508 and QLH12016) alone or together with other treatments for prostate cancer that has spread to other parts of the body. It may be an option if standard treatments have stopped working or caused side effects.
This trial tests a new experimental drug (TYK-00540) combined with enzalutamide, an approved hormone therapy, for men with advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The goal is to see if the combination can slow cancer growth better than current options.
This trial tests a new drug combination (GZ17-6.02) for men with advanced prostate cancer that has stopped responding to standard hormone therapies. The goal is to see if the drug can help slow down the cancer.
This trial tests a new drug called QLS2401 for patients with advanced prostate cancer that has spread and no longer responds to standard treatments. The goal is to see if it can help control the cancer.
This study tests a new drug called CP-PCA07 combined with enzalutamide for men whose prostate cancer has stopped responding to enzalutamide or abiraterone. The goal is to see if the combination is safe and can help control the cancer.
Hear when a new Prostatic Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.